Leading statins equally cardioprotective in head-to-head trial
Rosuvastatin carries a higher risk of new-onset diabetes and cataract surgery compared with atorvastatin, doctors say.
Rosuvastatin and atorvastatin are equally effective in cutting the risk of death and cardiac events despite greater LDL cholesterol lowering with rosuvastatin, show results from a head-to-head trial.
At the same time, rosuvastatin therapy carries a higher risk of new-onset diabetes and cataract surgery compared with atorvastatin, according to the South Korean researchers.
